Michael J Marino, PhD, received his PhD in 1995 from the University of Pittsburgh Department of Neuroscience where he employed behavioral and electrophysiological methods to the study of G-proteins and G-protein coupled receptors. As a postdoctoral fellow with Dr Jeff Conn at Emory University, he performed pioneering work on the role of metabotropic glutamate receptors in regulating the circuitry of the basal ganglia. This work led to the identification of potential targets for the treatment of Parkinson's disease. In 2001, he joined Merck Research Laboratories where he worked on novel drug discovery projects related on the modulatory control of brain circuitry underlying Parkinson's disease and related movement disorders. He joined Cephalon, Inc. in 2005 and is currently Associate Director of CNS biology at Cephalon, where he continues to focus on drug discovery for disorders of the CNS. He has published over 40 scientific articles, book chapters, and reviews.

Robert E Davis, PhD, has spent almost 25 years in the discovery and development of small molecule drugs for human disease. Dr Davis has worked in large and start-up pharmaceutical companies. He currently serves as the President of 3D Pharmaceutical Consultants. In this role, he provides strategic and operational consulting services to small and large pharmaceutical companies. Before founding this firm he served as Executive Vice President of Drug Discovery and Development for ACADIA Pharmaceuticals Inc holding that position since February 2001.

He also was a founding member of ACADIA's Scientific Advisory Board from 1996 and served as a consultant to ACADIA from November 2000 until becoming an employee. From January 1994 until October 2000, Dr Davis held various positions at MitoKor, a development stage biotechnology company, serving at various times as its President, Chief Executive Officer and Chief Scientific Officer. This company was recently sold to another company.

Earlier in his career, Dr Davis held various positions at Parke-Davis Pharmaceutical Research, Warner-Lambert Company including Director of Neurodegenerative Diseases. While at Parke-Davis, Dr Davis has chaired or participated in research and development teams that advanced 12 new chemical entities into human clinical trials, including Cognex, the first drug approved by the FDA and other countries for Alzheimer's disease.

Herbert Y Meltzer received his AB with honors in Chemistry from Cornell, MA in Chemistry from Harvard, and MD from Yale. Dr Meltzer is Bixler/May/Johnson Professor of Psychiatry and Pharmacology and Director of the Psychobiology Program for Translational Research at the Vanderbilt University School of Medicine, Chairman of the International Psychopharmacology Algorithm Project, Chair of the Young Investigator Grant Review for NARSAD, and Director of the Schizophrenia Program of Centerstone Mental Health System. Dr Meltzer has been president of the Collegium Internationale Neuropsychopharmacologicum (CINP) and the American College of Neuropsychopharma-cology (ACNP). He served as editor of 'Psychopharmacology: The Third Generation of Progress' and co-editor of the ACNP journal, 'Neuropsychopharmacology.' He has received the Noyes Prize of the Commonwealth of Pennsylvania, the Edward J Sachar Award from Columbia University, the Lieber Prize from NARSAD, the Stanley Dean Award of the American College of Psychiatry for his research on schizophrenia, the Gold Medal Award of the Society of Biological Psychiatry, the Earl Sutherland Prize for Lifetime Achievement in Research of Vanderbilt University (2004), and the Research Prize of the American Psychiatric Association (2005). Dr Meltzer is a member of the editorial board of numerous scientific journals. His research interests include: the psychopharmacology of schizophrenia, the mechanism of action of antipsychotic drugs, genetic factors in schizophrenia and pharmacogenomics, prevention of suicide in schizophrenia, and cognitive impairment in schizophrenia.

Lars J S Knutsen began his research career at Glaxo in Ware, Herts., UK having completed an MA in Chemistry at Christ Church, Oxford, in 1978. While at Glaxo he completed a PhD in Nucleoside Chemistry joining Novo Nordisk in Denmark in 1986. While there he led the project that identified tiagabine, a marketed anticonvulsant acting by blocking GABA uptake. In 1997, he joined Vernalis (Cerebrus) in the UK, initiating the adenosine A2A antagonist project that led to V2006, currently in clinical trials with Biogen-IDEC for Parkinson's disease. He joined Ionix Pharmaceuticals Ltd., in Cambridge, UK in 2002 as Director of Chemistry. Dr Knutsen joined the CNS Medicinal Chemistry group at Cephalon Inc. in 2006. He has over 35 peer-reviewed publications and 18 issued US patents.

Michael Williams, PhD, DSc, received his PhD (1974) from the Institute of Psychiatry and his Doctor of Science degree in Pharmacology (1987) both from the University of London. Dr Williams has worked in the US-based pharmaceutical industry for 30 years at Merck, Sharp and Dohme Research Laboratories, Nova Pharmaceutical, CIBA-Geigy, and Abbott Laboratories. He retired from the latter in 2000 as Divisional Vice President, Neurological and Urological Diseases Research and after serving as a consultant with various biotechnology/pharmaceutical/venture capital companies in the US, Canada and Europe, joined Cephalon, Inc. in West Chester, in 2003 where he is Vice President of Worldwide Discovery Research. He has published some 300 articles, book chapters and reviews and is an Adjunct Professor in the Department of Molecular Pharmacology and Biological Chemistry at the Feinberg School of Medicine, Northwestern University, Chicago, Illinois.

© 2007 Elsevier Ltd. All Rights Reserved Comprehensive Medicinal Chemistry II

No part of this publication may be reproduced, stored in any retrieval system or transmitted ISBN (set): 0-08-044513-6 in any form by any means electronic, electrostatic, magnetic tape, mechanical, photocopying, recording or otherwise, without permission in writing from the publishers ISBN (Volume 6) 0-08-044519-5; pp. 17-44

Blood Pressure Health

Blood Pressure Health

Your heart pumps blood throughout your body using a network of tubing called arteries and capillaries which return the blood back to your heart via your veins. Blood pressure is the force of the blood pushing against the walls of your arteries as your heart beats.Learn more...

Get My Free Ebook

Post a comment